Nobivac®

EDGE™ DAPPv

Canine EDGE DAPPv is a 0.5mL, combined vaccination approved for protection against canine distemper virus, adenovirus type 1 (hepatitis), canine parainfluenza virus, and canine parvovirus.

NOBIVAC EDGE DAPPV PROVIDES PROTECTION AGAINST FOUR KNOWN VIRUSES IN A 0.5 ML VACCINE

Canine Distemper Virus, Canine Adenovirus 1 (hepatitis), Canine Parainfluenza Virus, Canine Parvovirus (modified live viruses).

  • Protects against all known strains of CPV, including CPV-2c2,3
  • High antigenic mass (titer), low passage parvovirus vaccine
  • Canine vaccine containing CPV-2b, one of the most prevalent field strains of parvovirus
  • Protects against adenovirus type 1 that causes hepatitis in dogs
  • Provides disease coverage for commonly spread canine viruses, distemper, adenovirus types 1, parainfluenza and parvovirus in 1 formula

INDICATIONS:

Effective for the vaccination against distemper, adenovirus type 1 (hepatitis), parainfluenza, and parvovirus in one formula.

Recommended for use in healthy dogs 6 weeks of age or older.

Efficacy & Comparisons

NOBIVAC EDGE™ DAPPV—A PROVEN FOUNDATION FOR VACCINE PROTOCOLS

D–CANINE DISTEMPER VIRUS (CDV)

  • Onderstepoort-type strain in Nobivac® vaccines provides a high level of safety1

A–CANINE ADENOVIRUS TYPE 2 (CAV-2)

  • Protection against CAV-1 (hepatitis) without the side effects associated with modified live CAV-1 vaccines4

P–CANINE PARAINFLUENZA VIRUS (CPIV)

  • Systemic administration stimulates a strong IgG response1

PROTECT AGAINST ALL KNOWN STRAINS OF CANINE PARVOVIRUS (CPV), INCLUDING CPV-2C

PROVEN IN AN INDEPENDENT STUDY BY LARSON AND SCHULTZ2

  • No clinical signs of disease were seen in Nobivac-vaccinated puppies after challenge with mixed CPV-2b and CPV-2c strains2
  • First published data showing protection against CPV-2c challenge2
  • All vaccinated puppies were protected from disease
  • All control puppies developed disease and 50% died or were euthanized

No items to show.

Loading…

NOBIVAC EDGE DAPPV IS A SAFE CHOICE

  • Safety confirmed in 346-dog field study1
  • Proven safe across a variety of dog breeds and ages
  • Featuring an even higher level of quality due to VacciPure filtration

ADMINISTRATION AND DOSAGE

  • Subcutaneous injection
  • Primary vaccination may begin as early as 6 weeks
  • Repeat at 2 to 4 week intervals until the dog is 12 weeks of age
  • The need for annual revaccination has not been established
  • Available in a 25 x 0.5 mL dose presentation

ALSO AVAILABLE IN OTHER FORMULATIONS

Professional Resources and Educational Materials

Keep your clinic and staff informed and aware of diseases and outbreaks.

AAHA Canine Vaccination Guidelines

In-depth information about canine vaccinations and veterinary best practices.

Download

Nobivac® Social Media Kits

Digital Assets

Use these ready-to-share posts to educate pet parents and drive business to your clinic for preventative care.

Download

Quick Guide to Lepto

eBook

A handy guide to protect dogs and prevent the spread of leptospirosis.

Download

No items to show.

Loading…

References:

1. Data on file, Merck Animal Health. 

2. Larson LJ, Schultz RD. Do two current canine parvovirus type 2 and 2b vaccines provide protection against the new type 2c variant? Vet Ther. 2008;9(2):94–101. 

3. Schultz RD, Thiel B, Mukhtar E, Sharp P, Larson LJ. Age and long-term protective immunity in dogs and cats. J Comp Pathol. 2010;142 Suppl 1:S102–S108. 

4. Greene C, Rupprecht C. Rabies and other lyssavirus infections. In: Greene CE, ed. Infectious Diseases of the Dog and Cat. 3rd ed. St. Louis, MO: Saunders/Elsevier; 2006:167–183. 

8. Spibey N, Greenwood NM, Sutton D, Chalmers WS, Tarpey I. Canine parvovirus type 2 vaccine protects against virulent challenge with type 2c virus. Vet Microbiol. 2008;128(1-2) :48-55.

View All Nobivac References